Inhibitors of 3-hydroxy-3-methylgluttaryl coenzyme A (HMG-CoA) reductase, or statins, are used extensively to reduced elevated lipid levels and reduce cardiovascular risk. However, accumulated evidence suggests that stains not only act by lowering cholesterol levels, but also exert pleiotropic effects on many essential cellular functions including cell proliferation, differentiation, and survival and participate in the regulation of cell shape and motility. Thus cardiovascular benefit is provided by lowering raised cholesterol levels and by modulation of the inflammatory component of this disease. Such an anti-inflammatory effect may also benefit patients with autoimmune rheumatic disease. This overview assesses the evidence for using statins in patients with rheumatoid arthritis and systemic lupus erythematosus (SLE).
Maron DJ , Fazio S , Linton MF.Current perspectives on statins . Circulation2000; 101: 207-223 .
2.
Tsunekawa T , Hayashi T , Kano Het al.Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days . Circulation2001; 104: 376-379 .
3.
Buchwald H , Campos CT , Boen JRet al. for the POSCH group . Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH) . J Am Coll Cardiol1995; 26: 351-357 .
4.
Baetta R , Camera M , Comparato Cet al.Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering . Arterioscler Thromb Vasc Biol2002; 22: 692-692 .
5.
Kobashigawa JA , Katznelson S , Laks Het al.Effect of pravastatin on outcomes after cardiac transplantation . N Engl J Med1995; 333: 621-627 .
6.
Wenke K , Meiser B , Thiery Jet al.Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial . Circulation1997; 96: 1398-1402 .
7.
Schönbeck U , Libby P.Inflammation, immunity, and HMG-CoA reductase inhibitors . Statins as anti-inflammatory agents? Circulation2004; 109(Suppl. II): II-18-II-26 .
8.
Halcox JPJ , Deanfield JE.Beyond the laboratory. Clinical implications for statin pleiotropy . Circulation2004; 109 (Suppl. II): II-42-II-48 .
9.
McKay A , Leung BP , McInnes IB , Thomson NC , Liew FY.A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma . J Immunol2004; 172: 2903-2908 .
10.
Jakobisiak M , Golab J.Potential antitumor effects of statins (Review) . Int J Oncol2003; 23: 1055-1069 .
11.
Anderson KM , Wilson PW , Odell PM , Kannel WB.An updated coronary risk profile. A statement for health professionals . Circulation1991; 83: 356-362 .
12.
Bessant R , Hingorani A , Patel Let al.Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus . Rheumatology2004; 43: 924-929 .
13.
Ehrenstein MR , Jury E , Mauri C.Statins for atherosclerosis: as good as it gets ? New Engl J Med2005; 352: 73-75 .
14.
Kwak B , Mulhaupt F , Myit S , Mach F.Statins as a newly recognized type of immunomodulator . Nat Med2000; 6: 1399-1399 .
15.
Sadeghi MM , Tiglio A , Sadigh Ket al.Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors . Transplantation2001; 71: 1262-1268 .
16.
Kwak B , Mulhaupt F , Veillard N , Pelli G , Mach F.The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells . Swiss Med Wkly2001; 131: 41-46 .
17.
Muczynski KA , Ekle DM , Coder DM , Anderson SK.Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression . J Am Soc Nephrol2003; 14: 1336-1348 .
18.
Abusamieh M , Ash J.Atherosclerosis and systemic lupus erythematosus . Cardiol Rev2004; 12: 267-275 .
19.
Turesson C.Endothelial expression of MHC class II molecules in autoimmune disease . Curr Pharm Des2004; 10: 129-143 .
20.
Aktas O , Waiczies S , Smorodchenko Aet al.Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin . J Exp Med2003; 197: 725-733 .
21.
Youssef S , Stuve O , Patarroyo JCet al.The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease . Nature2002; 420: 78-84 .
22.
Leung BP , Sattar N , Crilly Aet al.A novel anti-inflammatory role for simvastatin in inflammatory arthritis . J Immunol2003; 170: 1524-1530 .
23.
Neuhaus O , Strasser-Fuchs S , Fazekas Fet al.Statins as immuno-modulators. Comparison with interferon-b1b in MS . Neurology2002; 59: 990-997 .
24.
Vollmer T , Key L , Durkalski Vet al.Oral simvastatin treatment in relapsing-remitting multiple sclerosis . Lancet2004; 363: 1607-1608 .
25.
Abud-mendoza C , de la Fuente H , Cuevas-Orta Eet al.Therapy with statins in patients with refactory rheumatic diseases: a preliminary study . Lupus2003; 12: 607-611 .
26.
McCarey DW , McInnes IB , Madhok Ret al.Trail of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial . Lancet2004; 363: 2015-2021 .
27.
Nissen SE , Tucu EM , Schoenhagen Pet al.Effect of statin therapy on LDL-cholesterol, C-reactive protein, and the progression of coronary artery disease . New Engl J Med2005; 352: 29-38 .
28.
Ridker PM , Cannon CP , Morrow Det al.Clinical relevance of achieved C-reactive protein levels following treatment with statin therapy . New Engl J Med2005; 352: 20-28 .
29.
Jevnikar AM , Grusby MJ , Glimcher LH.Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice . J Exp Med1994; 179: 1137-1137 .
30.
Jacob CO , van der Meide PH , McDevitt HO.In vivo treatment of (NZB NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon . J Exp Med1987; 166: 798-798 .
31.
Hasegawa K , Hayashi T , Maeda K.Promotion of lupus in NZB NZWF1 mice by plasmids encoding interferon (IFN)-gamma but not by those encoding interleukin (IL)-4 . J Comp Pathol2002; 127: 1-1 .
32.
Yokoyama H , Takabatake T , Takaeda Met al.Up-regulated MHC-class II expression and gamma-IFN and soluble IL-2R in lupus nephritis . Kidney Int1992; 42: 755-755 .
33.
Lockshin MD , Salmon JE , Roman MJ.Atherosclerosis and lupus: a work in progress . Arthritis Rheum2001; 44: 2215-2215 .
34.
Hakamada-Taguchi R , Uehara Y , Kuribayashi Ket al.Inhibition of hydroxymethylglutaryl-coenzyme A reductase reduces Th1 development and promotes Th2 development . Circ Res2003; 93: 948-956 .
Jimenez-Alonso J , Jaimez L , Sabio JM , Hidalgo C , Leon L.Atorvastatin-induced reversible positive antinuclear antibodies . Am J Med2002; 112: 329-329 .
37.
Srivastana M , Rencic A , Diglio Get al.Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus . Arch Dermatol2003; 139: 45-49 .
38.
Antonov D , Kazandjieva J , Etugov D , Gospodinov D , Tsankov N.Drug-induced lupus erythematosus . Clin Dermatol2004; 22: 157-166 .
39.
Lawman S , Mauri C , Jury EC , Cook HT , Ehrenstein MR.Atorvastatin inhibits autoreactive B cell activation and delays lupus development in NZB/WF1 mice . J Immunol2004; 173: 7641-7646 .
40.
Fellstrom B , Holdaas H , Jardine AGet al.Assessment of Lescol in Renal Transplantation Study Investigators. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial . Kidney Int2004; 66: 1549-1555 .
41.
Bellosta S , Paoletti R , Corsini A.Safety of statins: focus on clinical pharmacokinetics and drug interactions . Circulation2004; 109(23 Suppl. 1): III50-III57 .
42.
Renders L , Mayer-Kadner I , Koch Cet al.Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients . Nephrol Dial Transplant2001; 16: 141-146 .
43.
Maltz HC , Balog DL , Cheigh JS.Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine . Ann Pharmacother1999; 33: 1176-1179 .
44.
Jones P , Kafonek S , Laurora I , Hunninghake D.Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) . Am J Cardiol1998; 81: 582-587 .
45.
Schonbeck U , Gerdes N , Varo Net al.Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells . Circulation2002; 106: 2888-2893 .
46.
Semb AG , van Wissen S , Ueland Tet al.Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy . J Am Coll Cardiol2003; 41: 275-279 .
47.
Nishibori M , Takahashi HK , Mori S.The regulation of ICAM-1 and LFA-1 interaction by autacoids and statins: a novel strategy for controlling inflammation and immune responses . J Pharmacol Sci2003; 92: 7-12 .
48.
Weitz-Schmidt G , Welzenbach K , Brinkmann Vet al.Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site . Nat Med2001; 7: 687-692 .
49.
Chung HK , Lee IK , Kang Het al.Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells . Exp Mol Med2002; 34: 451-461 .
50.
Rasmussen LM , Hansen PR , Nabipour MTet al.Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells . Biochem J2001; 360: 363-370 .
51.
Xu ZM , Zhao SP , Li QZ , Nie S , Zhou HN.Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome . Clin Chim Acta2003; 338: 17-24 .
52.
Kaneider NC , Reinisch CM , Dunzendorfer Set al.Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin . Atherosclerosis2001; 158: 23-33 .
53.
Kato T , Hashikabe H , Iwata C , Akimoto K , Hattori Y.Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells . Biochim Biophys Acta2004; 1689: 267-272 .
54.
Buemi M , Allegra A , Senatore Met al.Pro-apoptotic effect of fluvastatin on human smooth muscle cells . Eur J Pharmacol1999; 370: 201-203 .
55.
Chapman-Shimshoni D , Yuklea M , Radnay J , Shapiro H , Lishner M.Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9 . Exp Hematol2003; 31: 779-783 .
56.
Focking M , Besselmann M , Trapp T.Statins potentiate caspase-3 activity in immortalized murine neurons . Neurosci Lett2004; 355: 41-44 .
57.
Kabouridis PS , Janzen J , Magee AL , Ley SC.Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signalling pathways in T lymphocytes . Eur J Immunol2000; 30: 954-963 .
58.
Yokoyama K , Ishibashi T , Ohkawara Het al.HMG-CoA reductase inhibitors suppress intracellular calcium mobilization and membrane current induced by lysophosphatidylcholine in endothelial cells . Circulation2002; 105: 962-967 .
59.
Goldman F , Hohl RJ , Crabtree J , Lewis-Tibesar K , Koretzky G.Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras . Blood1996; 88: 4611-4619 .
60.
Dichtl W , Dulak J , Frick Met al.HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells . Arterioscler Thromb Vasc Biol2003; 23: 58-63 .
61.
Liao JK.Isoprenoids as mediators of the biological effects of statins . J Clin Invest2002; 110: 285-288 .
62.
Hillyard DZ , Jardine AG , McDonald KJ , Cameron AJ.Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes . Atherosclerosis2004; 172: 219-228 .
63.
Silvius JR.Role of cholesterol in lipid raft formation: lessons from lipid model systems . Biochim Biophys Acta2003; 1610: 174-183 .
64.
Janes PW , Ley SC , Magee AI , Kabouridis PS.The role of lipid rafts in T cell antigen receptor (TCR) signalling . Sem Immunol2000; 12: 23-34 .
65.
Razzaq TM , Ozegbe P , Jury ECet al.Regulation of T-cell receptor signalling by membrane microdomains . Immunology2004; 113: 413-426 .
66.
Xavier R , Brennan T , Li Q , McCormack C , Seed B.Membrane compartmentation is required for efficient T cell activation . Immunity1998; 8: 723-732 .
67.
Silvius JR.Mechanisms of Ras protein targeting in mammalian cells . J Membr Biol2002; 190: 83-92 .
68.
Jury EC , Kabouridis PS , Abba A , Mageed RA , Isenberg DA.Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus . Arthritis Rheum2003; 48: 1343-1354 .
69.
Jury EC , Kabouridis PS , Flores-Borja F , Mageed RA , Isenberg DA.Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus . J Clin Invest2004; 113: 1176-1187 .
70.
Krishnan S , Nambiar MP , Warke VGet al.Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus . J Immunol2004; 172: 7821-7831 .
71.
Simons K , Ehehalt R.Cholesterol, lipid rafts, and disease . J Clin Invest2002; 110: 597-603 .
72.
Gringhuis SI , Leow A , Papendrecht-van der Voort EAMet al.Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid lymphocytes in rheumatoid arthritis . J Immunol2000; 164: 2170-2179 .
